MYO1C and myeloid sarcoma: The newlydeveloped mgt.PHEMA microspheres conjugated with a potential disease biomarker,p46/Myo1C protein, are thus a promising tool for affinity purification ofantibodies, which can improve diagnosis and treatment of MS patients.